Physician profile
Anu Gulati
NPI 1265519524
$707.00
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $69.81 · 2021: $245 · 2022: $149 · 2023: $66.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $148.81 | 2019-2022 | |
| Abbott Laboratories | $141.30 | 2021-2022 | |
| Pfizer INC. | $96.12 | 2019-2023 | |
| Novo Nordisk INC | $82.96 | 2020-2022 | |
| Glaxosmithkline, LLC. | $32.40 | 2020-2021 | |
| Horizon Therapeutics Plc | $30.78 | 2019 | |
| Amgen INC. | $29.54 | 2019 | |
| Lilly USA, LLC | $27.15 | 2019-2021 | |
| Allergan, INC. | $25.50 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.33 | 2021 | |
| Esperion Therapeutics, INC. | $16.48 | 2020 | |
| Genentech USA, INC. | $14.73 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.12 | 2020 | |
| Amarin Pharma, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.